Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry-Reference-Cited by-同舟云学术

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

Published:2019-10-31 Issue:1 Volume:75 Page:116-126
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Ariëns Lieneke F. M.¹^ORCID,Schaft Jorien¹,Bakker Daphne S.¹,Balak Deepak¹,Romeijn Margreet L. E.²,Kouwenhoven Tessa³,Kamsteeg Marijke³,Giovannone Barbara¹,Drylewicz Julia⁴^ORCID,Amerongen Cynthia Catalina Aurora²,Delemarre Evelien M.⁴,Knol Edward F.¹⁴,Wijk Femke⁴,Nierkens Stefan⁴,Thijs Judith L.¹^ORCID,Schuttelaar Marie L. A.³,Bruin‐Weller Marjolein S.¹^ORCID

Affiliation:

1. Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht Utrecht The Netherlands

2. Department of Dermatology University Medical Center Groningen University of Groningen Groningen The Netherlands

3. Department of Dermatology Radboud University Medical Center Nijmegen Nijmegen The Netherlands

4. Laboratory of Translational Immunology University Medical Center Utrecht Utrecht The Netherlands

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14080

Reference20 articles.

1. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

2. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

3. Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ);Bruin‐Weller M;Br J Dermatol,2017

4. Participation in a Clinical Trial Enhances Adherence and Persistence to Treatment

5. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of Inflammatory Mediators and Metabolome in Interstitial Fluid Collected with Dermal Open Flow Microperfusion before and at the End of Dupilumab Treatment in Atopic Dermatitis;Journal of Proteome Research;2024-07-10

2. Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients;Clinical and Experimental Dermatology;2024-06-11

3. ATOPİK DERMATİT TEDAVİSİNDE BİYOLOJİK İLAÇLAR: LİTERATÜR TARAMASI;Journal of Anatolian Medical Research;2024-06-11

4. Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155–1166;Journal of Medical Economics;2024-06-10

5. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities;JAAD International;2024-06